Product image of Nilotinib Pharmascience (Nilotinib) supplied by GNH India

Nilotinib Pharmascience

Active Ingredient:
Nilotinib
Origin:
EU

Nilotinib Pharmascience (Nilotinib)

Nilotinib, the active ingredient in Nilotinib Pharmascience, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It selectively inhibits the BCR‑ABL kinase and is indicated for the treatment of chronic myeloid leukemia in adult patients.

GNH India supplies Nilotinib Pharmascience as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Manufacturer / TM Owner

Pharmascience International Ltd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Nilotinib is employed in the management of BCR‑ABL positive leukemias, primarily chronic myeloid leukemia.

  • Chronic myeloid leukemia (chronic phase): improves disease control and prolongs survival.
  • Chronic myeloid leukemia (accelerated phase): helps achieve hematologic and cytogenetic responses.
  • Chronic myeloid leukemia (blast phase): provides targeted therapy when combined with other agents.

How It Works

  • Nilotinib selectively binds to the ATP‑binding site of the BCR‑ABL tyrosine kinase, preventing phosphorylation of downstream substrates. This blockade inhibits the proliferative signaling pathways that drive leukemic cell growth, leading to apoptosis and reduced disease progression in BCR‑ABL positive chronic myeloid leukemia.

Side Effects

Nilotinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: loose stools, often self‑limiting.
  • Rash: skin erythema or maculopapular eruptions.
  • Elevated liver enzymes: increased ALT/AST levels.
  • Fatigue: general tiredness or weakness.
  • Myalgia: muscle aches or discomfort.

Serious or Rare Side Effects

  • Cardiovascular events: arterial occlusive disease or ischemic heart disease.
  • Pancreatitis: inflammation of the pancreas, presenting with abdominal pain.
  • Severe hepatic injury: marked elevation of liver enzymes or jaundice.
  • QT interval prolongation: risk of cardiac arrhythmia.
  • Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Hematologic abnormalities: neutropenia, thrombocytopenia, or anemia.

Precautions & Warnings

When prescribing or dispensing Nilotinib, consider the following safety measures.

  • Cardiac monitoring: assess baseline ECG and monitor QT interval during therapy.
  • Liver function: evaluate hepatic enzymes before initiation and periodically thereafter.
  • Pancreatic enzymes: check amylase and lipase levels regularly.
  • Drug interactions: review concomitant medications that may affect CYP3A4 metabolism.
  • Pregnancy and lactation: avoid use in pregnant or breastfeeding women unless clearly justified.
  • Store at ambient temperature: keep below 25°C, retain in original packaging, and protect from moisture.

Avoid Interactions

Nilotinib interacts with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce Nilotinib exposure.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase risk of toxicity.
  • QT‑prolonging agents (e.g., amiodarone, fluoroquinolones): may exacerbate cardiac risk.

Moderate Interactions (Monitor Closely)

  • Antacids containing aluminum or magnesium: may lower absorption; separate dosing by at least 2 hours.
  • Proton‑pump inhibitors: potential reduction in bioavailability; monitor therapeutic response.
  • Statins metabolized by CYP3A4 (e.g., simvastatin): increased plasma levels; consider dose adjustment.
  • Herbal supplements (e.g., St. John's wort): possible induction of CYP3A4, reducing efficacy.
  • Vaccines: live attenuated vaccines should be avoided during treatment.

Frequently Asked Questions

Nilotinib Pharmascience is a prescription‑only tyrosine kinase inhibitor indicated for the treatment of adult patients with chronic myeloid leukemia (CML) that is positive for the BCR‑ABL fusion gene. It targets the underlying molecular driver of the disease to help control leukemic cell growth.

Nilotinib selectively binds to the ATP‑binding pocket of the BCR‑ABL tyrosine kinase, blocking its activity. By inhibiting this enzyme, the drug prevents downstream signaling that promotes proliferation of leukemic cells, leading to reduced tumor burden and improved disease control.

The specific dose of Nilotinib Pharmascience is determined by the treating physician based on the patient’s clinical status, disease phase, and tolerability. Only a qualified healthcare professional can prescribe the appropriate regimen.

Nilotinib is generally not recommended for use during pregnancy or while breastfeeding unless the potential benefit justifies the potential risk to the fetus or infant. Women of childbearing potential should use effective contraception during treatment and for a period after discontinuation as advised by their clinician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nilotinib belongs to the second‑generation BCR‑ABL inhibitors and offers higher potency and selectivity compared with first‑generation agents such as imatinib. Clinical studies have shown faster and deeper molecular responses, though safety profiles differ, requiring individualized assessment by the prescribing physician.

Nilotinib tablets should be stored at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid environments such as bathrooms.

Nilotinib is taken orally, usually as whole tablets with a moderate‑fat meal to improve absorption. Patients should swallow the tablets whole with water and follow the dosing schedule prescribed by their healthcare provider.

Serious risks include cardiovascular events such as arterial occlusive disease, QT interval prolongation leading to arrhythmias, severe hepatic injury, pancreatitis, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Patients should be monitored regularly for these complications.

Nilotinib is contraindicated in patients with known hypersensitivity to the drug or any of its excipients, and it should be avoided in individuals with a history of significant cardiovascular disease, uncontrolled QT prolongation, or severe hepatic impairment unless a specialist determines that benefits outweigh risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Nilotinib

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT